Oleclumab
Based on 1 publication(s) in Google Scholar
Oleclumab (MEDI9447) is a human IgG1λ monoclonal antibody targeting CD73 and inhibits the exonuclease activity of the extracellular enzyme CD73. Oleclumab can adjust the composition of bone marrow and lymphoid infiltrating leukocyte populations in the tumor microenvironment and has anti-tumor activity.
For research use only. We do not sell to patients.
- Purity: 99.90%
- CAS No.: 1803176-05-7
- Molecular Weight:143.14 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Oleclumab
More
Biological Activity
Human IgG1 lambda2
Human
NT5E/CD73
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Murine, Balb/c, syngeneic CT26 colon carcinoma tumor model[2]
-
Dosage:10 mg/kg
-
Administration:ip; 2 time per week, for 2 weeks
-
Result:Inhibited tumor growth by 50% or greater from study day 7 to study day 16 when compared with isotype control antibody-treated groups.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 lambda
ELISA, FACS, Functional assay
-
Immobilized CD73/5'-Nucleotidase Protein, Human (HEK293, His, HY-P70010) can bind Oleclumab. The EC50 for this effect is 3.27 ng/mL. -
Flow Cytometry analysis of A431 cells labelling NT5E/CD73 (red) with Oleclumab (anti-NT5E/CD73) (HY-P99039). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 lambda2 (HY-P990096). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS No. 1803176-05-7
-
Appearance Liquid
-
Molecular Weight 143.14 kDa
-
Color Colorless to light yellow
-
SMILES
[Oleclumab]
-
Synonyms
MEDI9447
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Roy S Herbst, et al. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 Apr 22;JCO2200227. [Content Brief]
[2]. Hay CM, et al. Targeting CD73 in the tumor microenvironment with MEDI9447. Oncoimmunology. 2016 Jul 11;5(8):e1208875. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)